L.K. Benson & Company P.C. Lowers Position in Abbott Laboratories $ABT

L.K. Benson & Company P.C. trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 11.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,564 shares of the healthcare product maker’s stock after selling 321 shares during the quarter. L.K. Benson & Company P.C.’s holdings in Abbott Laboratories were worth $349,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ABT. Brighton Jones LLC raised its position in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after acquiring an additional 4,755 shares in the last quarter. Wealthcare Advisory Partners LLC grew its stake in shares of Abbott Laboratories by 8.4% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 13,282 shares of the healthcare product maker’s stock valued at $1,762,000 after purchasing an additional 1,024 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Abbott Laboratories by 17.0% in the first quarter. GAMMA Investing LLC now owns 38,467 shares of the healthcare product maker’s stock valued at $5,103,000 after buying an additional 5,590 shares in the last quarter. Simplicity Wealth LLC boosted its stake in shares of Abbott Laboratories by 115.2% in the first quarter. Simplicity Wealth LLC now owns 17,758 shares of the healthcare product maker’s stock valued at $2,356,000 after buying an additional 9,506 shares in the last quarter. Finally, Fiduciary Financial Group LLC boosted its position in Abbott Laboratories by 15.1% during the first quarter. Fiduciary Financial Group LLC now owns 3,289 shares of the healthcare product maker’s stock worth $409,000 after purchasing an additional 431 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Price Performance

ABT opened at $134.45 on Thursday. The stock has a fifty day moving average of $132.30 and a 200-day moving average of $131.48. The firm has a market capitalization of $234.00 billion, a P/E ratio of 16.85, a PEG ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same period last year, the business earned $1.14 EPS. The business’s quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s payout ratio is currently 29.57%.

Analyst Upgrades and Downgrades

ABT has been the subject of several analyst reports. Evercore ISI upped their target price on Abbott Laboratories from $140.00 to $144.00 and gave the company an “outperform” rating in a research note on Tuesday. The Goldman Sachs Group upped their target price on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Raymond James Financial reduced their price target on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a report on Friday, July 18th. Jefferies Financial Group upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and increased their price target for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. Finally, BTIG Research lowered their target price on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $146.24.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.